Dr. Reddy’s Laboratories Limited announced that Aurigene Oncology Limited, its wholly-owned subsidiary and a clinical-stage biotech company focused on novel cancer therapies, has presented the Phase 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study. This trial marks India’s first foray into autologous BCMA-directed CAR-T cell therapy for patients with relapsed/refractory multiple myeloma. The …